Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of Spermatogenesis Suppression After Oral Administration of Dimethandrolone Undecanote (DMAU) Alone or With Levonorgestrel (LNG) for 12 Weeks Versus Placebo Alone in Normal Men
Conditions
Interventions
Dimethandrolone-Undecanoate
Levonorgestrel 0.03 MG
+1 more
Locations
2
United States
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States
University of Washington Medical Center & Health Sciences
Seattle, Washington, United States
Start Date
April 16, 2018
Primary Completion Date
March 5, 2020
Completion Date
March 5, 2020
Last Updated
October 30, 2025
NCT06657443
NCT03986021
NCT07073963
NCT00104325
NCT07470866
NCT07388667
Lead Sponsor
Premier Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions